For Healthcare Professionals Only

Important Safety InformationPrescribing Information
Important Safety InformationPrescribing Information
Hero Image

Dosing

Simplified dosing, no guesswork needed

Hero Image

Dosing

Simplified dosing, no guesswork needed

swooshesswooshes

The IHEEZO® Difference

An easy fit for your workflow — no extra steps

Drop icon

Administer 3-drop dose via a sterile, single-use ampule

24 mg of chloroprocaine in 800 mg of gel per ampule

No contamination icon

Do not touch the dropper tip to any surface to avoid gel contamination1

21 minutes icon

IHEEZO achieves full anesthesia in under 90 seconds on average with 21.5 minute average duration2

Information icon

Advise patients that their eyes will be insensitive for up to 20 minutes1
Due to the effect of anesthetic, care should be taken to avoid accidental injuries

Click here to see the full Prescribing Information for IHEEZO.

IHEEZO Product Ampule
swooshesswooshes

Get started with IHEEZO®

Explore Options

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.

By clicking “Allow All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.